Imm.med.ncku.edu.tw

Immune checkpoint blockade (ICB) therapy is emerging as a promising approach for cancer immunotherapy by modulating the immunosuppressive tumor microenvironment. In particular, ICB therapy by monoclonal antibodies targeting the immune checkpoint programmed cell death protein 1 (PD1) or its predominant ligand, programmed death ligand 1 (PDL1 ... ................
................